Non-pharmaceutical treatment combats recurring Clostridium Difficile infections
Transplanting human donor fecal microbiota into the colon of a patient infected with Clostridiodes difficile (C. diff) may be the best treatment for those not helped by C. diff targeted antibiotics, according to an article in the Journal of the American Osteopathic Association.
C. diff is the most common healthcare-acquired infection in the United States. It affects nearly half a million patients each year and becomes a recurring infection for nearly a third of them. If untreated, C. diff can lead to sepsis and death.
“Twenty five years ago C. diff infections were easier to manage and often resolved with discontinuation of the initiating antibiotic,” says Robert Orenstein, DO, an infectious disease specialist at Mayo Clinic and lead author on this article. “However, these infections have become increasingly common and pernicious.”
The standard and FDA-approved treatment for C. diff is a course of oral vancomycin, an antibiotic. However, even the medications used to eliminate C. diff can perpetuate the infection by killing off beneficial microbes. Newer antibiotics that more specifically target C. diff have been developed but they can be prohibitively expensive, according to Dr. Orenstein.
“Think of your gut as a forest and C. diff as a weed,” says Dr. Orenstein. “In a thriving forest, weeds barely get a foothold. But if you burn the forest down, the weeds are going to flourish.”
Unlike antibiotics, which are destructive by definition, fecal transplants or microbial replacement therapies, repopulate the gut with a diverse group of microbes that may block the C. diff‘s spore from germinating and propagating disease via its toxins. Transplants have several delivery methods, including enemas, capsules and direct instillation, to replace the diverse flora that maintain health and improve metabolism.
Currently, there are no FDA-approved fecal transplant products and performing fecal transplants is considered an investigational procedure. Dr. Orenstein notes there are several companies with products in Phase 3 clinical trials that could come to market as early as 2020. For this reason he strongly urges healthcare providers to refer patients with recurrent C. diff for these trials rather than for fecal transplants. In the meantime, the FDA reserves fecal transplants for patients who have experienced a second recurrence (third episode) of C. diff infection.
C. diff is common in healthcare settings and public spaces and rarely causes problems in people with healthy gut microbiota and immune systems, according to researchers. However, people who are already ill and taking antibiotics, chemotherapy, or proton pump inhibitors–which all greatly disrupt the gut ecosystem–are at risk. Elderly patients are especially vulnerable.
Dr. Orenstein expects the new treatment options will improve outcomes but says physicians need to assume greater responsibility for prevention.
“One of the most effective things physicians can do is become more responsible with antibiotic prescriptions,” says Dr. Orenstein. “That means only prescribing when they are clearly indicated, not for colds or viral sinus infections. We also must be especially judicious with elderly patients.”
The Latest on: Fecal transplants
via Google News
The Latest on: Fecal transplants
- Gut bacteria can help rebuild the immune systemon December 2, 2020 at 10:27 am
A first-of-its-kind study shows how ‘good' genera of gut bacteria can help support the correct functioning of the immune system in humans.
- How Do Microbiota Transplants for Autism Affect Our Metabolome?on November 16, 2020 at 4:25 am
The body's vast colonies of bacteria and other non-human cells are collectively known as the microbiome. In the gut, they perform a wide array of critical tasks. Researchers have found that those with ...
- Doctors explain how patient died from fecal transplanton November 15, 2020 at 4:00 pm
Doctors have released new details about the death of a 73-year-old patient who underwent an experimental fecal transplant last spring and died of a subsequent E. coli infection. The report ...
- Poop transplant death linked to E. colion October 30, 2020 at 4:59 pm
Earlier this year, the US Food and Drug Administration issued a warning regarding the safety of so-called fecal microbiota transplants (FMTs). The bulletin came after two patients were infected ...
- Doctors report first death from fecal microbiota transplanton October 30, 2020 at 4:59 pm
This spring, the Food and Drug Administration (FDA) announced that a 73-year-old man had died and another person had become sick after receiving fecal microbiota transplants (FMTs). The donor ...
- Autism’s Gut Connection: Microbes Could Soon Lead to New Treatmentson October 13, 2020 at 8:22 pm
Researchers are finding clues to autistic behavior — in patients’ gut bacteria. Using fecal transplants to improve symptoms have shown promise in preliminary studies. By Adam Piore October 13, 2020 ...
- Consuming fecal microbiome capsules may prevent weight regain when dieting: Studyon September 1, 2020 at 3:15 pm
provided fecal samples that were processed into autologous fecal microbiota transplant, which are frozen, opaque and odorless capsules, the press release stated. The participants were then ...
- Poop transplant cures man's 'drunkenness disease'on August 18, 2020 at 11:22 am
One man was feeling drunk even though he didn’t drink any alcohol. The 47-year-old man had gut fermentation syndrome, also known as auto-brewery syndrome (ABS). This rare condition involves ...
- What Is Fecal Impaction?on August 13, 2020 at 7:43 am
If you often have trouble making bowel movements and have to take laxatives (drugs that help you go) on a regular basis, you could one day have a serious bowel problem called fecal impaction.
- Heart Transplanton August 6, 2020 at 2:17 pm
A heart transplant is surgery to take out a diseased heart and replace it with a donor heart. The doctor will make a cut in the skin over your breastbone (sternum). The cut is called an incision. Then ...
via Bing News